- 10:17 PM Where do economists' see Q2 GDP headed?
- 10:04 PM Revealed: Exposure of Indian realty cos to Dubai m...
- 09:59 PM Dubai debt crisis just a trigger, 4500 Nifty key: ...
- 09:16 PM Dubai crisis confirms undue leverage fears: Roubin...
- 08:26 PM Patni promoters to set up a VC fund: Sources
- 08:21 PM November 28-30: Events to watch out for
- 07:27 PM Barclays Bk, Calyon Bk move Bombay HC against Wock...
- 07:17 PM Nirmal Bang's after market report
- 07:13 PM Prestige Group to file DRHP soon: Sources
- 07:11 PM Karnataka govt approves Mittal's Rs 30K cr steel p...



Hyderabad, July 4
Pharma major Dr Reddy’s Laboratories is upbeat on its performance this year in view of the revenues from upsides and possible higher profits from its German arm, Betapharm. In the third quarter of 2008-09, the Hyderabad-based company would exclusively distribute Sumatriptan, used for the treatment of acute migraine, in the US.
“Sumatriptan enjoys widespread market acceptability and I see other upsides as well. My belief is that the worst in Germany is probably over in terms of further margin pressures,” Dr K. Anji Reddy, Chairman of Dr Reddy’s told investors in the annual report of the company for the year 2007-08.
By migrating production of an increasing number of formulations to facilities in India, Dr Reddy’s, which posted a 23-per cent dip in its turnover at Rs 5,001 crore in 2007-08, should generate higher profits from Betapharm in the current financial year, the Chairman said.
Conceding that 2007-08 was a “worse year financially” compared to the previous year, Dr Reddy said he was expecting a topline growth of 25 per cent in rupee terms in the current year.
“This is a do-able target and I expect it to be achieved because of the changes that have been brought about, across the company, that are now primed to deliver superior financial results,” he claimed.
During 2007-08, Rs 629.5 crore was invested in manufacturing, R&D facilities and other capital expenditure making it the highest investment in a single financial year. It would create the capacity to support Dr Reddy’s Lab’s strategic growth agenda, he added.
Taken from Business Line
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- Dubai crisis: Which Indian companies may be affected
- 10 companies that MF managers love
- Dubai jitters: Will bears overtake investor confidence now?
- Global mkts panic on Dubai's debt rescheduling
- Indian mkts rattled from Dubai default impact

- Mkts singe in Dubai crisis, end down despite smart recovery
- Ganeshaspeaks: Market prediction for Nov 27
- Should you stop picking stocks?
- Ashwani Gujral's top five picks for today's trade

- China`s 50-year bond
Source: ft.com
- Lanco Infra tying up funds for three power projects
Source: Business Line
- RIL units to get 20% of gas needs from D-6
Source: Business Line
- No need to ban cotton export, says Maran
Source: Business Line










